Drug profile

The FDA adverse-event record for Infectious Bovine Rhinotracheitis Virus, Passage C-13;Bovine Viral Diarrhea Viru

10 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Infectious Bovine Rhinotracheitis Virus, Passage C-13;Bovine Viral Diarrhea Viru. See the species affected, top reactions, and outcomes below.

10
adverse-event reports
90.0%
death-coded share
Cattle
most-reported species
7
Death - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
9
Deaths Reported
90.0%
Death Rate

Active Ingredients

Infectious Bovine Rhinotracheitis Virus, Passage C-13;Bovine Viral Diarrhea Viru

Administration Routes

SubcutaneousIntramuscularUnknown

Species Affected

Cattle 10

Most Affected Breeds

Mixed (Cattle) 10

Most Reported Reactions

Death 7
Lack of efficacy - NOS 4
Lack of efficacy (bacteria) - NOS 3
Unrelated death 1
INEFFECTIVE, ANTIBIOTIC 1
Other abnormal test result NOS 1
CULTURE/TITER DATA ABNORMAL 1
Generalised allergic reaction NOS 1
Local swelling (not application site) 1
Dyspnoea 1
Respiratory sound 1
Unexplained death 1

Outcome Breakdown

Died
9 (47.4%)
Outcome Unknown
8 (42.1%)
Ongoing
1 (5.3%)
Recovered with Sequela
1 (5.3%)

Infectious Bovine Rhinotracheitis Virus, Passage C-13;Bovine Viral Diarrhea Viru Adverse Event Insights

10 reports name Infectious Bovine Rhinotracheitis Virus, Passage C-13;Bovine Viral Diarrhea Viru; 9 recorded a death outcome (90.0% of reported events, not a population-level mortality rate). Active ingredient: Infectious Bovine Rhinotracheitis Virus, Passage C-13;Bovine Viral Diarrhea Viru. Administration routes: Subcutaneous, Intramuscular, Unknown.

By species: Cattle (10 reports). By breed: Mixed (Cattle) (10).

Leading clinical signs: Death (7), Lack of efficacy - NOS (4), Lack of efficacy (bacteria) - NOS (3), Unrelated death (1). Outcome, 19 coded reports: Died leads at 47.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.